Commit To Buy Retrophin At $10, Earn 28.9% Annualized Using Options
StockOptionsChannel.com - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Retrophin, Inc. shares, but cautious about paying the going market price of $12.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RTRX: 12.92 (+0.19)
Attention Retrophin, Inc. (RTRX) Shareholders: Retrophin Mislead Investors According to a Newly Filed Class Action
GlobeNewswire - Mon Dec 22, 7:18PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 13, 2013 and September 30, 2014. Retrophin is a biopharmaceutical company that develops, acquires, and commercializes therapies for the treatment of serious, catastrophic, and rare diseases.
RTRX: 12.92 (+0.19)
The Winners for Best and Worst Biotech CEOs of 2014 Are...
at The Street - Thu Dec 18, 9:01AM CST
Congrats to David Schenkhein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
BLUE: 88.76 (+3.23), RTRX: 12.92 (+0.19), AGIO: 109.67 (+2.45)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Retrophin, Inc. and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX
GlobeNewswire - Tue Dec 16, 3:54PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
Retrophin Announces Addition to the NASDAQ Biotechnology Index
Business Wire - Tue Dec 16, 7:00AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
RTRX: 12.92 (+0.19)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Retrophin, Inc. of Class Action Lawsuit and Upcoming Deadline -- RTRX
GlobeNewswire - Fri Dec 12, 6:43PM CST
Pomerantz LLP has filed a class action lawsuit against Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Fri Dec 12, 3:59PM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of purchasers of the securities of Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Retrophin, Inc. and Lead Plaintiff Deadline of December 19, 2014
PR Newswire - Fri Dec 12, 9:00AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased shares of Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
SHAREHOLDER ALERT: Investigation on Behalf of Retrophin, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Thu Dec 11, 12:54PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Retrophin, Inc.
Business Wire - Wed Dec 10, 5:13PM CST
Glancy Binkow & Goldberg LLP reminds investors of Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Retrophin, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX
GlobeNewswire - Mon Dec 08, 12:12PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 11.83 (+0.76), STEM: 0.90 (+0.03), RTRX: 12.92 (+0.19), RGLS: 14.78 (+0.24), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Retrophin, Inc. To Contact Brower Piven Before The December 19, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Mon Dec 01, 4:00PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)
Ousted Retrophin CEO Sold Stock While Urging Investors to Buy
at The Street - Tue Nov 25, 11:41AM CST
Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.
RTRX: 12.92 (+0.19)
InsiderInsights.com Daily Round Up 11/24/14: CLD, OPK, HTZ, DEI
InsiderInsights - at Seeking Alpha - Tue Nov 25, 10:03AM CST
SNBC: 19.69 (-0.29), JASN: 9.84 (-0.06), HTZ: 24.38 (-0.09), APAM: 49.54 (-0.27), MMI: 33.68 (+0.05), STX: 68.82 (+0.17), DEI: 28.75 (-0.13), MRD: 18.64 (-0.53), PAH: 23.00 (+0.01), SGM: 12.35 (+0.05), CLD: 9.45 (-0.26), W: 20.44 (-0.35), SHOO: 31.55 (-0.09), INT: 47.79 (-0.05), OPK: 9.63 (+0.21), RTRX: 12.92 (+0.19), SFXE: 4.42 (+0.04), NNBR: 19.77 (+0.26), APD: 148.58 (unch)
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action against Retrophin, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 19, 2014
Business Wire - Mon Nov 24, 3:52PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. ("Retrophin" or the "Company"
RTRX: 12.92 (+0.19)